Autism Spectrum Disorder Trial, Recruiting NCT04446442 Sponsor: University of Texas Southwestern Medical Center Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT04446442
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The participant should be between 4 and 17 years old
  • The participant should have been diagnosed with Autism Spectrum Disorder (ASD) using a specific standard assessment tool called the ADOS-2
  • The participant should have an IQ score of 70 or above
  • The participant should be able to speak using simple, flexible sentences on their own (not just repeating words or phrases)

Who may not be able to join:

  • People who have brain implants, metal implants, a pacemaker, or any other medical devices implanted in their body
  • People who have been diagnosed with epilepsy (a condition that causes seizures)
  • People who have hearing or vision problems that have not been fully corrected
  • People who have had a brain injury in the past
  • People who have a known brain condition or abnormality that is not related to their autism diagnosis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Peter Tsai, MD, PhD, University of Texas Southwestern Medical Center

Phone: 214-648-3577

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
4 June 2019
Est. completion
31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of tDCS associated side effects assessed by tDCS Safety Assessment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov